JP2021529169A5 - - Google Patents

Info

Publication number
JP2021529169A5
JP2021529169A5 JP2020570726A JP2020570726A JP2021529169A5 JP 2021529169 A5 JP2021529169 A5 JP 2021529169A5 JP 2020570726 A JP2020570726 A JP 2020570726A JP 2020570726 A JP2020570726 A JP 2020570726A JP 2021529169 A5 JP2021529169 A5 JP 2021529169A5
Authority
JP
Japan
Prior art keywords
therapeutic composition
composition according
rest
inhibitor
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020570726A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021529169A (ja
JP7555542B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/037754 external-priority patent/WO2019246112A1/en
Publication of JP2021529169A publication Critical patent/JP2021529169A/ja
Publication of JP2021529169A5 publication Critical patent/JP2021529169A5/ja
Priority to JP2024043444A priority Critical patent/JP2024075673A/ja
Application granted granted Critical
Publication of JP7555542B2 publication Critical patent/JP7555542B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020570726A 2018-06-18 2019-06-18 統合失調症及び他の神経精神障害の治療方法 Active JP7555542B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024043444A JP2024075673A (ja) 2018-06-18 2024-03-19 統合失調症及び他の神経精神障害の治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862686346P 2018-06-18 2018-06-18
US62/686,346 2018-06-18
PCT/US2019/037754 WO2019246112A1 (en) 2018-06-18 2019-06-18 Methods of treating schizophrenia and other neuropsychiatric disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024043444A Division JP2024075673A (ja) 2018-06-18 2024-03-19 統合失調症及び他の神経精神障害の治療方法

Publications (3)

Publication Number Publication Date
JP2021529169A JP2021529169A (ja) 2021-10-28
JP2021529169A5 true JP2021529169A5 (cg-RX-API-DMAC7.html) 2022-05-19
JP7555542B2 JP7555542B2 (ja) 2024-09-25

Family

ID=67297259

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020570726A Active JP7555542B2 (ja) 2018-06-18 2019-06-18 統合失調症及び他の神経精神障害の治療方法
JP2024043444A Pending JP2024075673A (ja) 2018-06-18 2024-03-19 統合失調症及び他の神経精神障害の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024043444A Pending JP2024075673A (ja) 2018-06-18 2024-03-19 統合失調症及び他の神経精神障害の治療方法

Country Status (6)

Country Link
EP (1) EP3806861A1 (cg-RX-API-DMAC7.html)
JP (2) JP7555542B2 (cg-RX-API-DMAC7.html)
KR (1) KR102847197B1 (cg-RX-API-DMAC7.html)
CN (1) CN112566640A (cg-RX-API-DMAC7.html)
CA (1) CA3103663A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019246112A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120754249A (zh) * 2021-09-30 2025-10-10 上海鲸奇生物科技有限公司 直接转分化治疗神经系统疾病
US20230241118A1 (en) * 2021-10-20 2023-08-03 University Of Rochester Rejuvenation treatment of age-related white matter loss
EP4674962A1 (en) * 2023-02-28 2026-01-07 The University of Osaka Oligonucleotide, and rest expression suppressing agent and pharmaceutical composition using same

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5935811A (en) 1995-03-03 1999-08-10 California Institute Of Technology Neuron-restrictive silencer factor nucleic acids
US20080119427A1 (en) 1996-06-06 2008-05-22 Isis Pharmaceuticals, Inc. Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US6838283B2 (en) 1998-09-29 2005-01-04 Isis Pharmaceuticals Inc. Antisense modulation of survivin expression
BRPI0008131B8 (pt) 1999-02-12 2021-05-25 Daiichi Sankyo Co Ltd composto ou um sal deste, análogo de oligonucleotídeo, composição farmacêutica, sonda para um gene,iniciador para começar a amplificação, uso de um análogo de oligonucleotídeo ou de um sal deste farmacologicamente aceitável, agente antisentido, e, agente antígeno
US7098192B2 (en) 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
US7179796B2 (en) 2000-01-18 2007-02-20 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
WO2003070918A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
US20030027153A1 (en) * 2001-01-09 2003-02-06 Meyer Joanne M. Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia
JP2005504020A (ja) 2001-07-03 2005-02-10 アイシス・ファーマシューティカルス・インコーポレーテッド ヌクレアーゼ耐性キメラオリゴヌクレオチド
EP1857547B2 (en) 2002-08-05 2020-12-02 Silence Therapeutics GmbH Further novel forms of interfering RNA molecules
EP1393776A1 (en) * 2002-08-14 2004-03-03 Erasmus University Medical Center Rotterdam Use of genes identified to be involved in tumor development for the development of anti-cancer drugs and diagnosis of cancer
EP2182063A3 (en) 2003-09-18 2012-07-18 Isis Pharmaceuticals, Inc. Modulation of EIF4E expression
JP4428296B2 (ja) 2005-06-10 2010-03-10 セイコーエプソン株式会社 表示パネルモジュールおよび表示装置
EP2206724A1 (en) 2005-12-13 2010-07-14 Kyoto University Nuclear reprogramming factor
DK3399025T3 (da) 2007-03-23 2025-06-16 Wisconsin Alumni Res Found Omprogrammering af somatiske celler
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
EP2195029A2 (en) 2007-08-24 2010-06-16 Oryzon Genomics SA Treatment and prevention of neurodegenerative diseases
EP2315829B1 (en) 2008-08-08 2015-02-11 Mayo Foundation For Medical Education And Research Induced pluripotent stem cells
WO2011031998A1 (en) * 2009-09-11 2011-03-17 Isis Pharmaceuticals, Inc. Modulation of re1 silencing transcription factor expression
WO2011062963A2 (en) 2009-11-17 2011-05-26 Vitro Diagnositics, Inc. Induced puripotent stem cells and related methods
US9005967B2 (en) 2010-01-22 2015-04-14 Kyoto University Myc variants improve induced pluripotent stem cell generation efficiency
KR101235256B1 (ko) * 2010-09-13 2013-02-21 서울대학교산학협력단 miRNA를 타겟으로 한 신경퇴행성 질환 치료

Similar Documents

Publication Publication Date Title
Lau et al. An aging, pathology burden, and glial senescence build-up hypothesis for late onset Alzheimer’s disease
Wu et al. Functional roles and networks of non-coding RNAs in the pathogenesis of neurodegenerative diseases
Matos et al. Machado–Joseph disease/spinocerebellar ataxia type 3: lessons from disease pathogenesis and clues into therapy
Lee et al. miR‐206 regulates brain‐derived neurotrophic factor in Alzheimer disease model
JP2025172101A (ja) ドライアイの治療用医薬組成物
CN103189069B (zh) 以miRNA为靶的神经退行性疾病的治疗
US11221329B2 (en) Treatment of neurological and neurodevelopmental diseases and disorders associated with aberrant ion channel expression and activity
Hennig et al. Transcription coactivators p300 and CBP are necessary for photoreceptor-specific chromatin organization and gene expression
US10801027B2 (en) Inhibitors of SRSF1 to treat neurodegenerative disorders
JP2022511568A5 (cg-RX-API-DMAC7.html)
US12157889B2 (en) Methods to detect motor neuron disease comprising micro-RNAs
JP2022515881A (ja) オリゴ核酸分子及びその応用
Li et al. Ube2c-inhibition alleviated amyloid pathology and memory deficits in APP/PS1 mice model of AD
Fang et al. Silencing miR-155–5p alleviates hippocampal damage in kainic acid-induced epileptic rats via the Dusp14/MAPK pathway
Gomaa et al. Prasugrel anti-ischemic effect in rats: modulation of hippocampal SUMO2/3-IкBα/Ubc9 and SIRT-1/miR-22 trajectories
US20200071699A1 (en) Treatment of alzheimers disease with micro rna and ghrelin
Yuan et al. Upregulation of miR-424 inhibit retinal endothelial cells proliferation under high glucose condition via cyclin D1.
KR102360028B1 (ko) Smurf2의 저해제를 포함하는 세포 또는 개체의 노화를 감소시키기 위한 조성물 및 그의 용도
KR20250109188A (ko) 알츠하이머병 및 기타 뇌 질환을 치료하는 조성물 및 방법
Bayram et al. Decreased hdac1 gene expression in patients with alzheimer’s disease
CN112779252B (zh) 靶向SMN2启动子区MeCP2结合的关键甲基化区域的反义寡核苷酸
Schroeder et al. Genetic and pharmacological reversibility of phenotypes in mouse models of autism spectrum disorder
WO2025264967A1 (en) Agents and/or compositions useful for modulating cis-regulatory elements in synucleinopathies and methods for identifying agents and compositions thereof
CN118217303A (zh) miR-4763-3p或其拮抗剂在制备用于缓解/治疗认知衰退的药物中的应用
CN121313658A (zh) circAgtpbp1在制备治疗和/或预防视神经损伤的药物中的应用